We are a privately held medical diagnostics and therapeutics company dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Through the licensing, development and commercialization of novel technologies, NexEos Bio is bringing new tools and therapies to market that address the unmet needs of patients suffering with eosinophil-related diseases. Our lead program, NDX-3315, is a novel, non-invasive imaging agent for the diagnosis, treatment monitoring, and management of Eosinophilic Esophagitis (EoE). Additionally we have a therapeutics program that is applicable in a number of eosinophilic mediated diseases, including atopic keratoconjunctivitis, chronic rhinosinusitis, EoE, and others.
We are passionate about our goal of helping patients to maintain a high quality of life and to slow the progression of eosinophil-related diseases.
Our company is founded based on the culmination of decades of research and clinical development in the field of eosinophil-mediated diseases. Our team has collectively worked in the eosinophil field since its early days and have an understanding of the challenges that patients face from diagnosis through management of the disease and its related debilitating symptoms.
The NexEos Bio management team, together with its collaborators at The University of Utah, is highly seasoned with several decades of experience in both the field of eosinophil research and the pharmaceutical industry.